Author:
Fast Hannah E.,Murthy Bhavini Patel,Zell Elizabeth,Meng Lu,Murthy Neil,Saelee Ryan,Lu Peng-jun,Kang Yoonjae,Shaw Lauren,Gibbs-Scharf Lynn,Harris LaTreace
Publisher
Centers for Disease Control MMWR Office
Subject
Health Information Management,Health, Toxicology and Mutagenesis,General Medicine,Health (social science),Epidemiology
Reference8 articles.
1. Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 Omicron and Delta variants.;Accorsi;JAMA,2022
2. Effectiveness of 2, 3, and 4 COVID-19 mRNA vaccine doses among immunocompetent adults during periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 sublineages predominated—VISION Network, 10 states, December 2021–June 2022.;Link-Gelles;MMWR Morb Mortal Wkly Rep,2022
3. Association of prior BNT162b2 COVID-19 vaccination with symptomatic SARS-CoV-2 infection in children and adolescents during Omicron predominance.;Fleming-Dutra;JAMA,2022
4. CDC. Interim clinical considerations for use of COVID-19 vaccines currently approved or authorized in the United States. Atlanta, GA: US Department of Health and Human Services, CDC; 2022. https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html
5. CDC. COVID data tracker. Vaccination delivery and coverage. Atlanta, GA: US Department of Health and Human Services, CDC; 2022. https://covid.cdc.gov/covid-data-tracker/#vaccine-delivery-coverage